Under the terms of the agreement, Pfizer will have access to DIR Technologies’ inspection and quality control solutions.
DIR Technologies, a provider of quality and process control solutions for pharmaceutical primary packaging, has entered into a five-year agreement with Pfizer. Under the terms of the agreement, Pfizer will have access to DIR Technologies’ inspection and quality control solutions. The agreement opens up opportunities for joint projects pertaining to both production and packaging processes.
Among the solutions involved in the agreement is DIR Technologies’ induction integrity verification system (I2VS), which was introduced more than a year ago. According to DIR Technologies, the system is the first in the global pharmaceuticals market to perform in-line inspection on 100% of induction sealed bottles at the speed of the machine throughput. The I2VS is a workflow solution and an inspection device. The source of any potential faulty seals is indicated in real time, yielding a high degree of process understanding and the ability for operators to not only help fix potential faulty seals immediately, but also prevent them from occurring in the first place. The I2VS enables a new level of quality assurance and process control.
DIR Technologies and Pfizer also will be working together on the development of a new inspection technology based on DIR’s advanced high-speed imaging capabilities. The new system is intended to perform 100% in-line inspection of tablets and capsules.
Source: DIR Technologies